The EDC Consolidation Play That Could Actually Fix Your Query Backlog
CRScube acquired Mednet in Nov 2025, uniting 84,000 site users under one AI-assisted EDC. Here's what that means for...
study startup
Fortrea’s $45M Early Phase Deal Sets a 90-Day Test for Sponsors With Active Studies
Fortrea's $45M buy of Worldwide Clinical Trials' Early Phase Services unit means active sponsors face contract novation, lab method...
When the Sponsor’s IT Goes Down, Your Trial Goes With It
Boston Scientific's August 2026 cyberattack knocked out global IT and shipping. Here's what that means for sites running active...
When Your CRO Gets Acquired Mid-Study, Your Site Feels It First
Curavit's acquisition of Lindus Health's CRO assets unifies 13,478 sites across 79 countries — but site teams will navigate...
When Your CMO Fails an FDA Inspection, Your Sites Pay the Price
Scholar Rock's BLA refiling for SMA drug apitegromab after Catalent Indiana's OAI classification shows how CMO inspection failures translate...
![Stack of documents clipped with a black binder clip on a wooden desk, with a pen and glasses nearby in sunlight] ,](https://www.clinicaltrialvanguard.com/wp-content/uploads/2026/07/your-recruitment-plan-is-failing-before-screening-even-start-750x575.png)
Your Recruitment Plan Is Failing Before Screening Even Starts
59% of sites report recruitment blocked by process inefficiencies—the bottleneck isn't patient supply, it's the workflow that never gets...
59% of Sites Are Losing Patients Before They Ever Screen — Here’s Where the Pipeline Actually Breaks
A new survey finds 59% of clinical trial sites lose eligible patients to process failures. Krishma Shah breaks down...
When Your CRO Merges Mid-Study, the Site Pays the Price
Caidya and Simbec-Orion's merger creates a 6-month operational danger zone for sites running active studies. Here's what sponsor clinops...
When Two CROs Become One, Sites Pay the Integration Tax
Caidya and Simbec-Orion's June 2026 merger creates real site-level friction: dual CTMS logins, monitoring model gaps, and budget renegotiations...
The $10B Integration Problem Vertex Hasn’t Solved Yet
Vertex's $10B Crinetics acquisition doubles its therapeutic footprint overnight. Here's what that means for site contracts, CTMS consolidation, and...